Geode Capital Management LLC recently announced the acquisition of new stake in Zomedica Corp (AMEX:ZOM). The institutional investor has increased its shareholding in the Healthcare company by 3.31% to 9.64 million shares with purchase of 0.31 million shares. This fresh investment now brings its stake to 0.98% valued currently at $1.93 million. In addition, ProShare Advisors LLC raised its holdings by 38380.0 to 2.99 million shares. And Brown Brothers Harriman & Co. has lifted its position by 7.92% or 0.18 million shares – to 2.47 million shares.
With over 10.68 million Zomedica Corp (ZOM) shares trading Friday and a closing price of $0.17 on the day, the dollar volume was approximately $1.82 million. The shares have shown a negative half year performance of -19.82% and its price on 01/12/24 gained nearly 5.67%. Currently, there are 979.95M common shares owned by the public and among those 934.84M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The top 3 mutual fund holders in Zomedica Corp are Vanguard Total Stock Market ETF, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market ETF owns 33.69 million shares of the company’s stock, all valued at over $6.74 million. Vanguard Extended Market Index Fu bought 95600.0 shares to see its total holdings expand to 13.41 million shares valued at over $2.68 million and representing 1.37% of the shares outstanding. Fidelity Extended Market Index Fu now owns shares totaling to 0.52% of the shares outstanding.
The company’s stock has a 5-day price change of -5.20% and -2.87% over the past three months. ZOM shares are trading -15.33% year to date (YTD), with the 12-month market performance down to -29.61% lower. It has a 12-month low price of $0.15 and touched a high of $0.34 over the same period. ZOM has an average intraday trading volume of 4.50 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.48%, -5.53%, and -11.03% respectively.
Institutional ownership of Zomedica Corp (AMEX: ZOM) shares accounts for 8.81% of the company’s 979.95M shares outstanding. Mutual fund holders own 2.33%, while other institutional holders and individual stakeholders account for 6.21% and 1.75% respectively.
It has a market capitalization of $161.02M and a beta (3y monthly) value of 1.03. The earnings-per-share (ttm) stands at -$0.02. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.39% over the week and 7.59% over the month.
Analysts forecast that Zomedica Corp (ZOM) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and -$0.01 for 2024. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$0.01 a year ago. Earnings per share for the fiscal year are expected to increase by 50.00%, and 0.00% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Zomedica Corp (ZOM) as a “Hold” at a consensus score of 3.00. Specifically, 0 Wall Street analysts polled rate the stock as a buy, while 1 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ZOM, a number of firms have released research notes about the stock. Dawson James stated their Buy rating for the stock in a research note on January 06, 2023, with the firm’s price target at $6.
